StockNews.com initiated coverage on shares of RedHill Biopharma (NASDAQ:RDHL – Get Free Report) in a report released on Monday. The brokerage set a “hold” rating on the biotechnology company’s stock.
RedHill Biopharma Stock Performance
RDHL opened at $5.23 on Monday. RedHill Biopharma has a 52 week low of $5.20 and a 52 week high of $20.27. The business has a fifty day simple moving average of $6.24 and a 200-day simple moving average of $28.15.
Institutional Trading of RedHill Biopharma
An institutional investor recently bought a new position in RedHill Biopharma stock. GAMMA Investing LLC bought a new position in shares of RedHill Biopharma Ltd. (NASDAQ:RDHL – Free Report) during the 4th quarter, according to the company in its most recent filing with the SEC. The fund bought 5,089 shares of the biotechnology company’s stock, valued at approximately $32,000. GAMMA Investing LLC owned 0.40% of RedHill Biopharma at the end of the most recent quarter. 7.20% of the stock is currently owned by hedge funds and other institutional investors.
RedHill Biopharma Company Profile
RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company develops and commercializes Talicia for the treatment of H. pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its pipeline consists of five therapeutic candidates, which are in clinical development include opaganib for treating patients hospitalized with SARS-CoV-2 severe COVID-19 pneumonia, advanced unresectable cholangiocarcinoma, prostate cancer, and nuclear radiation protection; RHB-107 (upamostat) for treating outpatients infected with SARS-CoV-2 (COVID-19 disease) and advanced unresectable cholangiocarcinoma; RHB-104 for Crohn's disease; RHB-102 (Bekinda) for the treatment of acute gastroenteritis and gastritis, irritable bowel syndrome with diarrhea, and oncology support anti-emetic; and RHB-204 for pulmonary nontuberculous mycobacteria infections caused by mycobacterium avium complex.
Further Reading
- Five stocks we like better than RedHill Biopharma
- 2 Fintech Stocks to Buy Now and 1 to Avoid
- Hims & Hers Earnings Could Be a Game Changer—What to Do Now
- What is a Dividend Harvesting Strategy and How Can Investors Profit from it?
- DeepSeek IPO Remains Far Off—Investors Eye 4 Chinese AI Stocks
- Stock Analyst Ratings and Canadian Analyst Ratings
- Mortgage Market Bottom? Why Rocket Companies Could Be a Buy
Receive News & Ratings for RedHill Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RedHill Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
